We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $866M
1-Year Est. Return 231.68%
This Fund
S&P 500
This Quarter Est. Return
+48.07%
1 Year Est. Return
+231.68%
3 Year Est. Return
+883.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$866M
AUM Growth
+$233M
Cap. Flow
+$9.94M
Cap. Flow %
1.15%
Top 10 Hldgs %
98.82%
Holding
29
New
6
Increased
6
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
GHRS icon
GH Research
GHRS
+$52.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$24.2M
3
PLRX icon
Pliant Therapeutics
PLRX
+$2.19M
4
CCCC icon
C4 Therapeutics
CCCC
+$1.12M
5
TRAW icon
Traws Pharma
TRAW
+$750K

Top Sells

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$38.4M
2
STOK icon
Stoke Therapeutics
STOK
+$23.3M
3
XNCR icon
Xencor
XNCR
+$6.47M
4
IMTX icon
Immatics
IMTX
+$2.05M
5
DSGN icon
Design Therapeutics
DSGN
+$1.27M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPRX
26
Eupraxia Pharmaceuticals
EPRX
$554M
$66.1K 0.01%
+10,000
New +$68.9K
IKT icon
27
Inhibikase Therapeutics
IKT
$328M
$40.6K ﹤0.01%
+20,000
New +$35.8K
DSGN icon
28
Design Therapeutics
DSGN
$785M
– –
-119,516
Closed -$1.27M
IBIO icon
29
iBio
IBIO
$80.4M
– –
-68,076
Closed -$129K
1
2

Similar funds

LA
LexAurum Advisors Overland Park, Kansas $866M AUM
PWM
Parkway Wealth Management Plano, Texas $866M AUM
LA
LM Advisors San Diego, California $866M AUM 26.16% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $864M AUM 906.77% 1-Year Est. Return
BBI
Baxter Bros Inc Riverside, Connecticut $864M AUM 15.83% 1-Year Est. Return
FTF
Freedom Together Foundation New York $867M AUM 20.05% 1-Year Est. Return
FI
Fractal Investments Glastonbury, Connecticut $867M AUM 23.63% 1-Year Est. Return
DOA
D'Orazio & Associates Falls Church, Virginia $864M AUM 21.64% 1-Year Est. Return

Lynx1 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Lynx1 Capital Management held 29 positions worth $866M, up 37% from $633M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Lynx1 Capital Management's Q2 2026 filing shows 6 new, 6 increased, 7 reduced and 2 closed positions. Its largest new stake was Pliant Therapeutics: 1,798,070 shares worth $2.05M. The largest sale was Denali Therapeutics, an estimated $38.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Lynx1 Capital Management's largest Q2 2026 buy was Pliant Therapeutics: 1,798,070 shares worth $2.05M.
  • Lynx1 Capital Management added most to GH Research in Q2 2026, an estimated $52.2M increase.
  • Lynx1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $38.4M.
  • Lynx1 Capital Management fully exited Design Therapeutics in Q2 2026, selling an estimated $1.27M.
  • Lynx1 Capital Management's ten largest holdings make up 99% of its $866M portfolio in Q2 2026.
  • Lynx1 Capital Management opened 6 new positions and closed 2 in Q2 2026.
  • Lynx1 Capital Management's portfolio value rose 37% quarter-over-quarter to $866M.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.